CN104039827B - 丝聚合蛋白原c末端结构域特异性抗体及其用途 - Google Patents

丝聚合蛋白原c末端结构域特异性抗体及其用途 Download PDF

Info

Publication number
CN104039827B
CN104039827B CN201280066201.0A CN201280066201A CN104039827B CN 104039827 B CN104039827 B CN 104039827B CN 201280066201 A CN201280066201 A CN 201280066201A CN 104039827 B CN104039827 B CN 104039827B
Authority
CN
China
Prior art keywords
filaggrin
profilaggrin
terminal domain
gene
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280066201.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104039827A (zh
Inventor
日比野利彦
山本真实
高木雅哉
坂部纯
坂部纯一
户仓新树
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Publication of CN104039827A publication Critical patent/CN104039827A/zh
Application granted granted Critical
Publication of CN104039827B publication Critical patent/CN104039827B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201280066201.0A 2011-11-09 2012-11-08 丝聚合蛋白原c末端结构域特异性抗体及其用途 Active CN104039827B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011245483A JP5771123B2 (ja) 2011-11-09 2011-11-09 プロフィラグリンｃ末端ドメイン特異的抗体及びその用途
JP2011-245483 2011-11-09
PCT/JP2012/079015 WO2013069741A1 (ja) 2011-11-09 2012-11-08 プロフィラグリンc末端ドメイン特異的抗体及びその用途

Publications (2)

Publication Number Publication Date
CN104039827A CN104039827A (zh) 2014-09-10
CN104039827B true CN104039827B (zh) 2016-12-14

Family

ID=48290111

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280066201.0A Active CN104039827B (zh) 2011-11-09 2012-11-08 丝聚合蛋白原c末端结构域特异性抗体及其用途

Country Status (7)

Country Link
US (2) US20140287431A1 (enExample)
EP (1) EP2778174B1 (enExample)
JP (1) JP5771123B2 (enExample)
KR (1) KR102025446B1 (enExample)
CN (1) CN104039827B (enExample)
ES (1) ES2650733T3 (enExample)
WO (1) WO2013069741A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
WO2020076770A1 (en) * 2018-10-08 2020-04-16 Yale University Selective binding and aggregation of human keratin in the skin barrier using human filaggrin subdomains sd67 and sd150

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023915A (zh) * 2006-02-16 2007-08-29 株式会社高丝 以桦树树液为有效成分的药效剂及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4162259B2 (ja) * 1991-04-26 2008-10-08 ビオメリュー・ソシエテ・アノニム リウマチ性関節炎抗体により認識される抗原、抗原製剤及びその適用方法
CA2570887C (en) * 2004-06-18 2014-09-16 Genentech, Inc. Tumor treatment
GB0525492D0 (en) * 2005-12-15 2006-01-25 Univ Dundee Filaggrin
WO2011068166A1 (ja) * 2009-12-03 2011-06-09 株式会社資生堂 ブレオマオシン水解酵素の活性を指標としたアトピー性皮膚炎による乾燥肌改善剤のスクリーニング方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023915A (zh) * 2006-02-16 2007-08-29 株式会社高丝 以桦树树液为有效成分的药效剂及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A homozygous frameshift mutation in the murine filaggrin gene facilitates enhanced percutaneous allergen priming;Padraic G. Fallon et al;《Nature Genetics》;20090531;第41卷(第5期);摘要、第602-606页、图2 *
ACCESSION NO.NM_002016.1;Vavrova K et al;《GenBank》;20080425;FEATURES、ORGIN部分 *

Also Published As

Publication number Publication date
CN104039827A (zh) 2014-09-10
EP2778174B1 (en) 2017-11-01
WO2013069741A1 (ja) 2013-05-16
EP2778174A4 (en) 2015-06-24
US20190079080A1 (en) 2019-03-14
HK1201856A1 (en) 2015-09-11
JP5771123B2 (ja) 2015-08-26
KR20140089366A (ko) 2014-07-14
KR102025446B1 (ko) 2019-09-25
JP2013100249A (ja) 2013-05-23
ES2650733T3 (es) 2018-01-22
EP2778174A1 (en) 2014-09-17
US20140287431A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
JP2014521098A (ja) 病理学バイオマーカーアッセイ
JP4012722B2 (ja) カルボキシメチル化ペプチドに対する抗体
CN104039827B (zh) 丝聚合蛋白原c末端结构域特异性抗体及其用途
CN116626294B (zh) 盘状结构域受体2在诊断神经退行性疾病中的应用及相关的计算机可读介质
CN103183726B (zh) 衍生自人bplp蛋白的肽、编码所述肽的多核苷酸和针对所述肽的抗体
JPH11242026A (ja) 腎疾患の検査方法
US20160370385A1 (en) Assay for anti-mullerian hormone
RU2739607C2 (ru) Специфически очищенные антитела против пресепсина
US20140193843A1 (en) Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker
JP5961608B2 (ja) ＥｐｈＡ４細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
Hok-A-Hin et al. Apolipoprotein L1 is increased in frontotemporal lobar degeneration post-mortem brain but not in ante-mortem cerebrospinal fluid
JP5943945B2 (ja) プロフィラグリンｃ末端ドメイン特異的抗体及びその用途
CN101466732A (zh) Iv型胶原样免疫反应性多肽
CN119546635A (zh) 新颖的可溶性尿激酶纤溶酶原激活物受体(suPAR)结合分子及其用途
EP2918600B1 (en) Novel peptide and use thereof
JP2915530B2 (ja) ラミニン フラグメント
HK1201856B (en) Antibody specific to profilaggrin c-terminal domain, and use thereof
CN112724236B (zh) 一种两性蛋白1的抗原肽及其抗体与应用
KR20250153269A (ko) 섬유아세포 활성화 마커 및 치료법에서의 tgfbi
JP4993065B2 (ja) 肝細胞癌の診断方法
JP2007332122A (ja) 抗ｎｃ１モノクローナル抗体反応性ペプチド
JP2008191135A (ja) 腎炎検出試薬
WO2001090196A1 (en) Immunoassay method for x-type phospholipase a¿2?
JPH11286500A (ja) ラミニンフラグメント測定方法
JP2011190202A (ja) サポシンａ特異的抗体及びその作成方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201856

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1201856

Country of ref document: HK